Company: OSRH
Filing Date: 2025-01-31
Form Type: 424B3
Source: 0001213900-25-008874
Chunk: 604

Company: OSR Holdings, Inc.
Filing Date: 2025-01-31
Form: 424B3
Chunk 604
---
 the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions and increased cyber -attacksagainst U.S. companies. Additionally, any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets. Any of the above mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting from the Russian invasion of Ukraine, the escalation of the Israel -Hamasconflict and subsequent sanctions or related actions, could adversely affect the Company’s search for an initial business combination and any target business with which we may ultimately consummate an initial business combination. The excise tax included in the Inflation Reduction Act of 2022 may decrease the value of the Company’s securities following its initial business combination, hinder its ability to consummate an initial business combination, and decrease the amount of funds available for distribution in connection with a liquidation. NOTE 6 — COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ deficit section of the Company’s balance sheets. The following is a reconciliation of the Company’s common stock subject to possible redemption as of December 31, 2023:

|                                                                         |     | Common     
 Stock      
 Subject to 
 Possible   
 Redemption |             |   |
|:------------------------------------------------------------------------|:----|:-----------|------------:|:--|
| Gross proceeds from Initial Public Offering                             |     | $          |  69,000,000 |   |
| Less: Proceeds allocated to public warrants and rights                  |     |            |  (1,236,527 | ) |
| Offering costs allocated to common stock subject to possible redemption |     |            |  (4,791,126 | ) |
| Less: Redemption of common stock in connection with Trust extension     |     |            | (35,995,728 | ) |
| Plus: Accretion on common stock subject to possible redemption          |     |            |   9,449,634 |   |
| Balance, December 31, 2023                                              |     | $          |  36,426,253 |   |

F-44 BELLEVUE LIFE SCIENCES ACQUISITION COR